Read by QxMD icon Read

GLP-1 diabetes

Shizuka Kaneko, Youhei Ueda, Yumiko Tahara
BACKGROUND: Enhanced Recovery After Surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing profound stress responses following surgery [Wilmore and Kehlet: BMJ 2001; 322(7284): 473-6]. Glucagon-like peptide-1 receptor agonists (GLP-1RAgs), such as liraglutide, have recently been widely used as antidiabetic agents in patients with type 2 diabetes (T2D) because they maintain blood glucose at an ideal level throughout the day, including during postprandial periods, thereby improving hypoglycemia and body weight more than insulin therapies...
December 11, 2018: European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes
Shanshan Wu, Le Gao, Andrea Cipriani, Yi Huang, Zhirong Yang, Jun Yang, Shuqing Yu, Yuan Zhang, Sanbao Chai, Zilu Zhang, Feng Sun, Siyan Zhan
AIM: To evaluate the comparative effects of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is), on beta-cell function and insulin resistance in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: Medline, Embase, the Cochrane Library and were searched for randomized controlled trials (RCTs) with duration≥4 weeks. Network meta-analysis was performed, followed by subgroup analysis and meta-regression...
December 9, 2018: Diabetes, Obesity & Metabolism
Nitesh D Kuhadiya, Ben Prohaska, Husam Ghanim, Paresh Dandona
OBJECTIVE: We tested the hypothesis that addition of GLP-1 receptor agonists (GLP-1RA) to insulin in c-peptide positive patients with T1D will result in a reduction in hemoglobin A1C (HbA1c) with reduced insulin requirements and a rise in c-peptide concentrations. METHODS: This is a retrospective analysis of 11 normal weight patients with T1D consecutively treated with GLP-1RA in addition to insulin. Paired t tests were used to compare the changes in HbA1c, insulin doses, body weight, body mass index, and C-peptide concentrations prior to and 12 ± 1 week after GLP-1RA therapy...
December 9, 2018: Diabetes, Obesity & Metabolism
Pengzhou Li, Liyong Zhu, Xiangwu Yang, Weizheng Li, Xulong Sun, Bo Yi, Shaihong Zhu
Type II diabetes is a complex, chronic, and progressive disease. Glucagon-like peptide-1 (7-36) amide (GLP-1) is a gut hormone released from the L cells which stimulate insulin secretion and promotes insulin gene expression and β-cell growth and differentiation. Elevated levels of hormones secreted by L cells are an essential reason for diabetes improvement. GLP-1 secretion has been reported to be regulated by farnesoid X receptor (FXR), a transcriptional sensor for bile acids which also acts on glucose metabolism...
December 7, 2018: Journal of Cellular Physiology
Samuel J P Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke, Barnaby Hunt
INTRODUCTION: Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia. METHODS: Outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9...
December 7, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Joseph Zhou, Anil Poudel, Prashanth Chandramani-Shivalingappa, Biao Xu, Ryan Welchko, Lixin Li
PURPOSE: Glucagon like peptide-1 (GLP-1) is produced to induce postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, has a protective effect on weight gain in obese subjects. Brown adipose tissue plays a major role in the control of energy balance and is known to be involved in the weight loss regulated by liraglutide. The putative anti-obesity properties of liraglutide and the cell signaling pathways involved were examined. METHODS: Four groups of C57/BL6 mice fed with chow or HFHS diet were injected with either liraglutide or vehicle for four weeks...
December 9, 2018: Endocrine
Maria Kalogirou, Emmanouil Sinakos
Nonalcoholic fatty liver disease (NAFLD) is highly associated with insulin resistance (IR), type 2 diabetes mellitus and metabolic syndrome, being characterized as the hepatic component of metabolic syndrome. Despite its high prevalence, no pharmacological treatment has been established, as of yet. A growing body of evidence, however, shows that reducing IR can result in improvement of the biochemical and histological features of nonalcoholic steatohepatitis (NASH)-the aggressive form of NAFLD that can lead to cirrhosis and hepatocellular carcinoma...
November 27, 2018: World Journal of Hepatology
Jordan Rowlands, Julian Heng, Philip Newsholme, Rodrigo Carlessi
The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its "incretin effect" in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a broader range of physiological effects in the body. Both in vitro and in vivo studies have demonstrated that GLP-1 mimetics alleviate endoplasmic reticulum stress, regulate autophagy, promote metabolic reprogramming, stimulate anti-inflammatory signaling, alter gene expression, and influence neuroprotective pathways. A substantial body of evidence has accumulated with respect to how GLP-1 and its analogs act to restore and maintain normal cellular functions...
2018: Frontiers in Endocrinology
Li Zhao, Chunfang Zhu, Meng Lu, Chi Chen, Xiaomin Nie, Buatikamu Abudukerimu, Kun Zhang, Zhiyuan Ning, Yi Chen, Jing Cheng, Fangzhen Xia, Ningjian Wang, Michael D Jensen, Yingli Lu
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an ideal therapy for type 2 diabetes and, as of recently, for obesity. In contrast to visceral fat, subcutaneous fat appears to be protective against metabolic diseases. Here, we aimed to explore whether liraglutide, a GLP-1RA, could redistribute body fat via regulating lipid metabolism in different fat depots. After being fed a high-fat diet for 8 weeks, 50 male Wistar and Goto-Kakizaki rats were randomly divided into a normal control group, a diabetic control group, low- and high-dose liraglutide-treated groups and a diet-control group...
February 1, 2019: Journal of Endocrinology
João Martins, Dongfei Liu, Flavia Fontana, Mónica Ferreira, Alexandra Correia, Silvia Valentino, Marianna Kemell, Karina Moslova, Ermei M Mäkilä, Jarno J Salonen, Jouni Hirvonen, Bruno Sarmento, Hélder A Santos
Microfluidics technology is emerging as a promising strategy to improve the oral delivery of proteins and peptides. Herein, a multistage drug delivery system is proposed as a step forward in the development of non-invasive therapies. Undecylenic acid modified thermally hydrocarbonized porous silicon (UnPSi) nanoparticles (NPs) were functionalized with the Fc fragment of immunoglobulin G for targeting purposes. Glucagon like peptide-1 (GLP-1) was loaded into the NPs as a model anti-diabetic drug. Fc-UnPSi NPs were coated with mucoadhesive chitosan, and ultimately entrapped into a polymeric matrix with pH-responsive properties by microfluidic nanoprecipitation...
December 7, 2018: ACS Applied Materials & Interfaces
Hanna Fjeldheim Dale, Caroline Jensen, Trygve Hausken, Einar Lied, Jan Gunnar Hatlebakk, Ingeborg Brønstad, Dag Arne Lihaug Hoff, Gülen Arslan Lied
The increased prevalence of lifestyle diseases, such as the metabolic syndrome and type 2 diabetes mellitus (T2DM), calls for more knowledge on dietary treatments targeting the specific metabolic pathways involved in these conditions. Several studies have shown a protein preload before a meal to be effective in lowering the postprandial glycaemic response in healthy individuals and patients with T2DM. The aim of the present study was to assess the effect of a marine protein hydrolysate (MPH) from Atlantic cod ( Gadus morhua ) on postprandial glucose metabolism in healthy, middle-aged to elderly subjects...
2018: Journal of Nutritional Science
Ankit Shah, Marlena M Holter, Fatima Rimawi, Victoria Mark, Roxanne Dutia, James McGinty, Bruce Levin, Blandine Laferrère
OBJECTIVE: Hepatic insulin clearance is a significant regulator of glucose homestasis. We hypothesized that the improvement in insulin clearance rates (ICRs) under fasting conditions and in response to oral and intravenous (IV) glucose would improve similarly after Roux-en-Y gastric bypass (RYGB) and adjustable gastric banding (AGB) as a function of weight loss; the difference in ICR after oral and IV glucose stimulation will be enhanced after RYGB compared with AGB, an effect mediated by glucagon-like peptide 1 (GLP-1)...
December 6, 2018: Diabetes Care
Qian-Feng Xiong, Shao-Hua Fan, Xin Zhang, Yu Niu, Xue-Wen Li, Ya-Wei Shi, Li-Hui Zhang
Glucagon-like peptide 1 (GLP-1), a neuroendocrine hormone produced by the gastrointestinal tract, plays a significant role in blood glucose regulation; drugs derived from GLP-1 are currently used for the treatment of type 2 diabetes. In addition to regulating glucose homeostasis, the protective effects of GLP-1 on the cardiovascular system are also of interest. However, the vascular protective mechanisms of GLP-1 remain unclear. The present study was designed to evaluate the role of GLP-1 in the proliferation and migration of vascular smooth muscle cells, and the underlying mechanisms...
December 1, 2018: Die Pharmazie
Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Teresa Guagnano, Armando Tartaro, Riccardo C Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli, Francesca Santilli
Thromboxane (TX)-dependent platelet activation and lipid peroxidation, as reflected in vivo by the urinary excretion of 11-dehydro-TXB₂ and 8-iso-prostaglandin (PG)F2α , play a key role in atherothrombosis in obesity and type 2 diabetes mellitus (T2DM) since the earlier stages. Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg/day) or lifestyle counseling until achieving a comparable weight loss (-7% of initial body weight), to assess whether changes in subcutaneous (SAT) and visceral (VAT) adipose tissue distribution (MRI), insulin sensitivity (Matsuda Index) and beta-cell performance (multiple sampling OGTT beta-index), with either intervention, might affect TX-dependent platelet activation, lipid peroxidation and inflammation...
December 2, 2018: Nutrients
Andre F Batista, Victor Bodart-Santos, Fernanda G De Felice, Sergio T Ferreira
The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's disease (PD) reflects an incomplete knowledge of the underlying disease processes. Considerable efforts have been made to investigate the central pathological features of these diseases, giving rise to numerous attempts to develop compounds that interfere with such features. However, further characterization of the molecular targets within the interconnected AD and PD pathways is still required. Impaired brain insulin signaling has emerged as a feature that contributes to neuronal dysfunction in both AD and PD, leading to strategies aiming at restoring this pathway in the brain...
December 3, 2018: CNS Drugs
Matthieu Chodorge, Anthony J Celeste, Joseph Grimsby, Anish Konkar, Pia Davidsson, David Fairman, Lesley Jenkinson, Jacqueline Naylor, Nicholas White, Jonathan C Seaman, Karen Dickson, Benjamin Kemp, Jennifer Spooner, Emmanuel Rossy, David C Hornigold, James L Trevaskis, Nicholas J Bond, Timothy B London, Andrew Buchanan, Tristan Vaughan, Cristina M Rondinone, Jane K Osbourn
Type 2 diabetes (T2D) is a complex and progressive disease requiring polypharmacy to manage hyperglycaemia and cardiovascular risk factors. However, most patients do not achieve combined treatment goals. To address this therapeutic gap, we have developed MEDI4166, a novel glucagon-like peptide-1 (GLP-1) receptor agonist peptide fused to a proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralising antibody that allows for glycaemic control and low-density lipoprotein cholesterol (LDL-C) lowering in a single molecule...
December 3, 2018: Scientific Reports
Jingbo Hu, Yongzhong Du
During the years, while treatment strategy for diabetes mellitus has improved, the incidence of diabetes worldwide increases continuously. Chronic kidney disease (CKD) is one of the major diabetic microvascular complications, and a primary cause leading to end-stage renal disease (ESRD). The progression to ESRD, affected by hyperglycemia and hypertension, is characterized by microalbuminuria and macroalbuminuria. With advances in understanding the pathogenesis of CKD in diabetic patients, many novel therapeutic targets have been proposed, and the corresponding agents are being developed continually to prevent the progression of CKD...
December 3, 2018: Expert Review of Clinical Pharmacology
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and suppress glucagon release via the stimulation of GLP-1 receptors. Although all GLP-1 RAs share the same underlying mechanism of action, they differ in terms of formulations, administration, injection devices and dosages. With six GLP-1 RAs currently available in Europe (namely, immediate-release exenatide, lixisenatide, liraglutide; prolonged-release exenatide, dulaglutide and semaglutide), each with its own characteristics and administration requirements, physicians caring for patients in their routine practice face the challenge of being cognizant of all this information so they are able to select the agent that is most suitable for their patient and use it in an efficient and optimal way...
November 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Maka S Hedrington, Stephen N Davis
Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction. Currently, all approved members of the class require administration by injection. Areas covered: This manuscript reviews oral semaglutide-an experimental GLP-1 receptor agonist in phase-3 clinical development. Available pharmacological and clinical data of the drug are reviewed, and important end-points described. Expert opinion: Oral peptide delivery has become possible with the discovery of absorption enhancers...
November 30, 2018: Expert Opinion on Pharmacotherapy
Annie Hasib, Ming T Ng, Neil Tanday, Sarah L Craig, Victor A Gault, Peter R Flatt, Nigel Irwin
BACKGROUND: Therapeutic benefits of peptide-based drugs is limited by rapid renal elimination. METHODS: Therefore, to prolong the biological action profile of the recently characterised triple-acting hybrid peptide, exendin-4/gastrin/xenin-8-Gln, a fatty-acid (C-16) has been covalently attached, creating exendin-4(Lys27 PAL)/gastrin/xenin-8-Gln. Exendin-4/gastrin and liraglutide/gastrin/xenin-8-Gln were also synthesised as direct comparator peptides. RESULTS: All hybrid peptides evoked significant concentration-dependent increases of insulin secretion from isolated murine islets and BRIN-BD11 cells...
November 30, 2018: Diabetes/metabolism Research and Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"